Search

Your search keyword '"Fischietti, Mariafausta"' showing total 162 results
Start Over Author "Fischietti, Mariafausta"
162 results on '"Fischietti, Mariafausta"'

1. B cell-based therapy produces antibodies that inhibit glioblastoma growth

Author

Wang, Si, Castro, Brandyn A., Katz, Joshua L., Arrieta, Victor, Najem, Hinda, Vazquez-Cervantes, Gustavo I., Wan, Hanxiao, Olson, Ian E., Hou, David, Dapash, Mark, Billingham, Leah K., Chia, Tzu- yi, Wei, Chao, Rashidi, Aida, Platanias, Leonidas C., McCortney, Kathleen, Horbinski, Craig M., Stupp, Roger, Zhang, Peng, Ahmed, Atique U., Sonabend, Adam M., Heimberger, Amy B., Lesniak, Maciej S., Riviere-Cazaux, Cecile, Burns, Terry, Miska, Jason, Fischietti, Mariafausta, and Lee-Chang, Catalina

Subjects
United States. National Cancer Institute -- Analysis, Thermo Fisher Scientific Inc., Biopharmaceutics -- Health aspects -- Analysis, Scientific equipment and supplies industry -- Health aspects -- Analysis, Viral antibodies -- Health aspects -- Analysis, Immunotherapy -- Analysis -- Health aspects, Ethylenediaminetetraacetic acid -- Analysis -- Health aspects, Brain tumors -- Prognosis, B cells -- Analysis -- Health aspects, Glioblastoma multiforme -- Prognosis, Vaccines -- Health aspects -- Analysis, Antibodies -- Health aspects -- Analysis, Health care industry
Abstract

Glioblastoma (GBM) is a highly aggressive and malignant brain tumor with limited therapeutic options and a poor prognosis. Despite current treatments, the invasive nature of GBM often leads to recurrence. A promising alternative strategy is to harness the potential of the immune system against tumor cells. Our previous data showed that the [B.sub.Vax] (B cell- based vaccine) can induce therapeutic responses in preclinical models of GBM. In this study, we aimed to characterize the antigenic reactivity of [B.sub.Vax]-derived Abs and evaluate their therapeutic potential. We performed immunoproteomics and functional assays in murine models and samples from patients with GBM. Our investigations revealed that [B.sub.Vax] distributed throughout the GBM tumor microenvironment and then differentiated into Ab-producing plasmablasts. Proteomics analyses indicated that the Abs produced by [B.sub.Vax] had unique reactivity, predominantly targeting factors associated with cell motility and the extracellular matrix. Crucially, these Abs inhibited critical processes such as GBM cell migration and invasion. These findings provide valuable insights into the therapeutic potential of [B.sub.Vax]-derived Abs for patients with GBM, pointing toward a novel direction for GBM immunotherapy., Introduction Glioblastoma (GBM) is an aggressive and malignant brain tumor that arises from glial cells (1). GBM is one of the most common and deadly forms of brain cancer in [...]

Published
2024
Full Text
View/download PDF

3. Combined PI3Kα-mTOR Targeting of Glioma Stem Cells

Author

Eckerdt, Frank D, Bell, Jonathan B, Gonzalez, Christopher, Oh, Michael S, Perez, Ricardo E, Mazewski, Candice, Fischietti, Mariafausta, Goldman, Stewart, Nakano, Ichiro, and Platanias, Leonidas C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Stem Cell Research - Nonembryonic - Non-Human, Clinical Research, Stem Cell Research - Nonembryonic - Human, Brain Cancer, Stem Cell Research, Brain Disorders, Cancer, Neurosciences, Brain Neoplasms, Cell Line, Tumor, Glioma, Humans, Neoplastic Stem Cells, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Spheroids, Cellular, TOR Serine-Threonine Kinases, Thiazoles
Abstract

Glioblastoma (GBM) is the most common and lethal primary intrinsic tumour of the adult brain and evidence indicates disease progression is driven by glioma stem cells (GSCs). Extensive advances in the molecular characterization of GBM allowed classification into proneural, mesenchymal and classical subtypes, and have raised expectations these insights may predict response to targeted therapies. We utilized GBM neurospheres that display GSC characteristics and found activation of the PI3K/AKT pathway in sphere-forming cells. The PI3Kα selective inhibitor alpelisib blocked PI3K/AKT activation and inhibited spheroid growth, suggesting an essential role for the PI3Kα catalytic isoform. p110α expression was highest in the proneural subtype and this was associated with increased phosphorylation of AKT. Further, employing the GBM BioDP, we found co-expression of PIK3CA with the neuronal stem/progenitor marker NES was associated with poor prognosis in PN GBM patients, indicating a unique role for PI3Kα in PN GSCs. Alpelisib inhibited GSC neurosphere growth and these effects were more pronounced in GSCs of the PN subtype. The antineoplastic effects of alpelisib were substantially enhanced when combined with pharmacologic mTOR inhibition. These findings identify the alpha catalytic PI3K isoform as a unique therapeutic target in proneural GBM and suggest that pharmacological mTOR inhibition may sensitize GSCs to selective PI3Kα inhibition.

Published
2020

4. Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms

Author

Saleiro, Diana, Wen, Jeremy Q., Kosciuczuk, Ewa M., Eckerdt, Frank, Beauchamp, Elspeth M., Oku, Chidera V., Blyth, Gavin T., Fischietti, Mariafausta, Ilut, Liliana, Colamonici, Marco, Palivos, William, Atsaves, Paula A., Tan, Dean, Kocherginsky, Masha, Weinberg, Rona Singer, Fish, Eleanor N., Crispino, John D., Hoffman, Ronald, and Platanias, Leonidas C.

Published
2022
Full Text
View/download PDF

5. m6A RNA methylation regulates mitochondrial function

Author

Kahl, Michael, primary, Xu, Zhaofa, additional, Arumugam, Saravanan, additional, Edens, Brittany, additional, Fischietti, Mariafausta, additional, Zhu, Allen C, additional, Platanias, Leonidas C, additional, He, Chuan, additional, Zhuang, Xiaoxi, additional, and Ma, Yongchao C, additional

Published
2024
Full Text
View/download PDF

6. Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma

Author

Fischietti, Mariafausta, Eckerdt, Frank, Blyth, Gavin T., Arslan, Ahmet D., Mati, William M., Oku, Chidera V., Perez, Ricardo E., Lee-Chang, Catalina, Kosciuczuk, Ewa M., Saleiro, Diana, Beauchamp, Elspeth M., Lesniak, Maciej S., Verzella, Daniela, Sun, Leyu, Fish, Eleanor N., Yang, Guang-Yu, Qiang, Wenan, and Platanias, Leonidas C.

Published
2021
Full Text
View/download PDF

10. FIGURE 4 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

Author

Saleiro, Diana, primary, Kosciuczuk, Ewa M., primary, Fischietti, Mariafausta, primary, Perez, Ricardo E., primary, Yang, G. Sohae, primary, Eckerdt, Frank, primary, Beauchamp, Elspeth M., primary, Hou, Ye, primary, Wang, Qixuan, primary, Weinberg, Rona Singer, primary, Fish, Eleanor N., primary, Yue, Feng, primary, Hoffman, Ronald, primary, and Platanias, Leonidas C., primary

Published
2023
Full Text
View/download PDF

11. Figure S1 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

Author

Saleiro, Diana, primary, Kosciuczuk, Ewa M., primary, Fischietti, Mariafausta, primary, Perez, Ricardo E., primary, Yang, G. Sohae, primary, Eckerdt, Frank, primary, Beauchamp, Elspeth M., primary, Hou, Ye, primary, Wang, Qixuan, primary, Weinberg, Rona Singer, primary, Fish, Eleanor N., primary, Yue, Feng, primary, Hoffman, Ronald, primary, and Platanias, Leonidas C., primary

Published
2023
Full Text
View/download PDF

12. FIGURE 1 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

Author

Saleiro, Diana, primary, Kosciuczuk, Ewa M., primary, Fischietti, Mariafausta, primary, Perez, Ricardo E., primary, Yang, G. Sohae, primary, Eckerdt, Frank, primary, Beauchamp, Elspeth M., primary, Hou, Ye, primary, Wang, Qixuan, primary, Weinberg, Rona Singer, primary, Fish, Eleanor N., primary, Yue, Feng, primary, Hoffman, Ronald, primary, and Platanias, Leonidas C., primary

Published
2023
Full Text
View/download PDF

13. FIGURE 2 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

Author

Saleiro, Diana, primary, Kosciuczuk, Ewa M., primary, Fischietti, Mariafausta, primary, Perez, Ricardo E., primary, Yang, G. Sohae, primary, Eckerdt, Frank, primary, Beauchamp, Elspeth M., primary, Hou, Ye, primary, Wang, Qixuan, primary, Weinberg, Rona Singer, primary, Fish, Eleanor N., primary, Yue, Feng, primary, Hoffman, Ronald, primary, and Platanias, Leonidas C., primary

Published
2023
Full Text
View/download PDF

14. FIGURE 3 from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

Author

Saleiro, Diana, primary, Kosciuczuk, Ewa M., primary, Fischietti, Mariafausta, primary, Perez, Ricardo E., primary, Yang, G. Sohae, primary, Eckerdt, Frank, primary, Beauchamp, Elspeth M., primary, Hou, Ye, primary, Wang, Qixuan, primary, Weinberg, Rona Singer, primary, Fish, Eleanor N., primary, Yue, Feng, primary, Hoffman, Ronald, primary, and Platanias, Leonidas C., primary

Published
2023
Full Text
View/download PDF

15. Data from Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells

Author

Saleiro, Diana, primary, Kosciuczuk, Ewa M., primary, Fischietti, Mariafausta, primary, Perez, Ricardo E., primary, Yang, G. Sohae, primary, Eckerdt, Frank, primary, Beauchamp, Elspeth M., primary, Hou, Ye, primary, Wang, Qixuan, primary, Weinberg, Rona Singer, primary, Fish, Eleanor N., primary, Yue, Feng, primary, Hoffman, Ronald, primary, and Platanias, Leonidas C., primary

Published
2023
Full Text
View/download PDF

17. Data from Myeloid-Derived Suppressive Cells Promote B cell–Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma

Author

Lee-Chang, Catalina, primary, Rashidi, Aida, primary, Miska, Jason, primary, Zhang, Peng, primary, Pituch, Katarzyna C., primary, Hou, David, primary, Xiao, Ting, primary, Fischietti, Mariafausta, primary, Kang, Seong Jae, primary, Appin, Christina L., primary, Horbinski, Craig, primary, Platanias, Leonidas C., primary, Lopez-Rosas, Aurora, primary, Han, Yu, primary, Balyasnikova, Irina V., primary, and Lesniak, Maciej S., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table S2 from SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression

Author

Fischietti, Mariafausta, primary, Eckerdt, Frank, primary, Perez, Ricardo E., primary, Guillen Magaña, Jamie N., primary, Mazewski, Candice, primary, Ho, Sang, primary, Gonzalez, Christopher, primary, Streich, Lukas D., primary, Beauchamp, Elspeth M., primary, Heimberger, Amy B., primary, Baran, Aneta H., primary, Yue, Feng, primary, James, C. David, primary, and Platanias, Leonidas C., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figures from Myeloid-Derived Suppressive Cells Promote B cell–Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma

Author

Lee-Chang, Catalina, primary, Rashidi, Aida, primary, Miska, Jason, primary, Zhang, Peng, primary, Pituch, Katarzyna C., primary, Hou, David, primary, Xiao, Ting, primary, Fischietti, Mariafausta, primary, Kang, Seong Jae, primary, Appin, Christina L., primary, Horbinski, Craig, primary, Platanias, Leonidas C., primary, Lopez-Rosas, Aurora, primary, Han, Yu, primary, Balyasnikova, Irina V., primary, and Lesniak, Maciej S., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figures S1-S3, Table S1 from SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression

Author

Fischietti, Mariafausta, primary, Eckerdt, Frank, primary, Perez, Ricardo E., primary, Guillen Magaña, Jamie N., primary, Mazewski, Candice, primary, Ho, Sang, primary, Gonzalez, Christopher, primary, Streich, Lukas D., primary, Beauchamp, Elspeth M., primary, Heimberger, Amy B., primary, Baran, Aneta H., primary, Yue, Feng, primary, James, C. David, primary, and Platanias, Leonidas C., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Tables and Figure Legends from Myeloid-Derived Suppressive Cells Promote B cell–Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma

Author

Lee-Chang, Catalina, primary, Rashidi, Aida, primary, Miska, Jason, primary, Zhang, Peng, primary, Pituch, Katarzyna C., primary, Hou, David, primary, Xiao, Ting, primary, Fischietti, Mariafausta, primary, Kang, Seong Jae, primary, Appin, Christina L., primary, Horbinski, Craig, primary, Platanias, Leonidas C., primary, Lopez-Rosas, Aurora, primary, Han, Yu, primary, Balyasnikova, Irina V., primary, and Lesniak, Maciej S., primary

Published
2023
Full Text
View/download PDF

22. Data from SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression

Author

Fischietti, Mariafausta, primary, Eckerdt, Frank, primary, Perez, Ricardo E., primary, Guillen Magaña, Jamie N., primary, Mazewski, Candice, primary, Ho, Sang, primary, Gonzalez, Christopher, primary, Streich, Lukas D., primary, Beauchamp, Elspeth M., primary, Heimberger, Amy B., primary, Baran, Aneta H., primary, Yue, Feng, primary, James, C. David, primary, and Platanias, Leonidas C., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 1 from Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors

Author

Fenton, Sarah E., primary, Zannikou, Markella, primary, Ilut, Liliana, primary, Fischietti, Mariafausta, primary, Ji, Chunni, primary, Oku, Chidera V., primary, Horvath, Curt M., primary, Le Poole, I. Caroline, primary, Bosenberg, Marcus, primary, Bartom, Elizabeth T., primary, Kocherginsky, Masha, primary, Platanias, Leonidas C., primary, and Saleiro, Diana, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figures and Supplementary Materials and Methods with References from Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors

Author

Fenton, Sarah E., primary, Zannikou, Markella, primary, Ilut, Liliana, primary, Fischietti, Mariafausta, primary, Ji, Chunni, primary, Oku, Chidera V., primary, Horvath, Curt M., primary, Le Poole, I. Caroline, primary, Bosenberg, Marcus, primary, Bartom, Elizabeth T., primary, Kocherginsky, Masha, primary, Platanias, Leonidas C., primary, and Saleiro, Diana, primary

Published
2023
Full Text
View/download PDF

25. Figure S4 from GADD45β Loss Ablates Innate Immunosuppression in Cancer

Author

Verzella, Daniela, primary, Bennett, Jason, primary, Fischietti, Mariafausta, primary, Thotakura, Anil K., primary, Recordati, Camilla, primary, Pasqualini, Fabio, primary, Capece, Daria, primary, Vecchiotti, Davide, primary, D'Andrea, Daniel, primary, Di Francesco, Barbara, primary, De Maglie, Marcella, primary, Begalli, Federica, primary, Tornatore, Laura, primary, Papa, Salvatore, primary, Lawrence, Toby, primary, Forbes, Stuart J., primary, Sica, Antonio, primary, Alesse, Edoardo, primary, Zazzeroni, Francesca, primary, and Franzoso, Guido, primary

Published
2023
Full Text
View/download PDF

26. Data from GADD45β Loss Ablates Innate Immunosuppression in Cancer

Author

Verzella, Daniela, primary, Bennett, Jason, primary, Fischietti, Mariafausta, primary, Thotakura, Anil K., primary, Recordati, Camilla, primary, Pasqualini, Fabio, primary, Capece, Daria, primary, Vecchiotti, Davide, primary, D'Andrea, Daniel, primary, Di Francesco, Barbara, primary, De Maglie, Marcella, primary, Begalli, Federica, primary, Tornatore, Laura, primary, Papa, Salvatore, primary, Lawrence, Toby, primary, Forbes, Stuart J., primary, Sica, Antonio, primary, Alesse, Edoardo, primary, Zazzeroni, Francesca, primary, and Franzoso, Guido, primary

Published
2023
Full Text
View/download PDF

27. Supplementary information from GADD45β Loss Ablates Innate Immunosuppression in Cancer

Author

Verzella, Daniela, primary, Bennett, Jason, primary, Fischietti, Mariafausta, primary, Thotakura, Anil K., primary, Recordati, Camilla, primary, Pasqualini, Fabio, primary, Capece, Daria, primary, Vecchiotti, Davide, primary, D'Andrea, Daniel, primary, Di Francesco, Barbara, primary, De Maglie, Marcella, primary, Begalli, Federica, primary, Tornatore, Laura, primary, Papa, Salvatore, primary, Lawrence, Toby, primary, Forbes, Stuart J., primary, Sica, Antonio, primary, Alesse, Edoardo, primary, Zazzeroni, Francesca, primary, and Franzoso, Guido, primary

Published
2023
Full Text
View/download PDF

28. Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors

Author

Fenton, Sarah E., primary, Zannikou, Markella, additional, Ilut, Liliana, additional, Fischietti, Mariafausta, additional, Ji, Chunni, additional, Oku, Chidera V., additional, Horvath, Curt M., additional, Le Poole, I. Caroline, additional, Bosenberg, Marcus, additional, Bartom, Elizabeth T., additional, Kocherginsky, Masha, additional, Platanias, Leonidas C., additional, and Saleiro, Diana, additional

Published
2023
Full Text
View/download PDF

30. EXTH-52. HARNESSING A B CELL THERAPY TO PROMOTE ANTI-GLIOBLASTOMA HUMORAL RESPONSE

Author

Castro, Brandyn, primary, Fischietti, Mariafausta, additional, Zolp, Andrew, additional, Zhao, Junfei, additional, Hou, David, additional, Nguyen, Linh, additional, Wan, Hanxiao, additional, Zhang, Peng, additional, Han, Yu, additional, Lopez-Rosas, Aurora, additional, Platanias, Leonidas, additional, Stupp, Roger, additional, Miska, Jason, additional, Lesniak, Maciej, additional, and Lee-Chang, Catalina, additional

Published
2022
Full Text
View/download PDF

31. SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression

Author

Fischietti, Mariafausta, primary, Eckerdt, Frank, additional, Perez, Ricardo E., additional, Guillen Magaña, Jamie N., additional, Mazewski, Candice, additional, Ho, Sang, additional, Gonzalez, Christopher, additional, Streich, Lukas D., additional, Beauchamp, Elspeth M., additional, Heimberger, Amy B., additional, Baran, Aneta H., additional, Yue, Feng, additional, James, C. David, additional, and Platanias, Leonidas C., additional

Published
2022
Full Text
View/download PDF

33. Low Radiation Environment Switches the Overgrowth-Induced Cell Apoptosis Toward Autophagy

Author

Fischietti, Mariafausta, primary, Fratini, Emiliano, additional, Verzella, Daniela, additional, Vecchiotti, Davide, additional, Capece, Daria, additional, Di Francesco, Barbara, additional, Esposito, Giuseppe, additional, Balata, Marco, additional, Ioannuci, Luca, additional, Sykes, Pamela, additional, Satta, Luigi, additional, Zazzeroni, Francesca, additional, Tessitore, Alessandra, additional, Tabocchini, Maria Antonella, additional, and Alesse, Edoardo, additional

Published
2021
Full Text
View/download PDF

35. Inhibitory effects of SEL201 in acute myeloid leukemia

Author

Kosciuczuk, Ewa M., primary, Kar, Aroop K., additional, Blyth, Gavin T., additional, Fischietti, Mariafausta, additional, Abedin, Sameem, additional, Mina, Alain A., additional, Siliezar, Rebekah, additional, Rzymski, Tomasz, additional, Brzozka, Krzysztof, additional, Eklund, Elizabeth A., additional, Beauchamp, Elspeth M., additional, Eckerdt, Frank, additional, Saleiro, Diana, additional, and Platanias, Leonidas C., additional

Published
2019
Full Text
View/download PDF

36. Myeloid-Derived Suppressive Cells Promote B cell–Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma

Author

Lee-Chang, Catalina, primary, Rashidi, Aida, additional, Miska, Jason, additional, Zhang, Peng, additional, Pituch, Katarzyna C., additional, Hou, David, additional, Xiao, Ting, additional, Fischietti, Mariafausta, additional, Kang, Seong Jae, additional, Appin, Christina L., additional, Horbinski, Craig, additional, Platanias, Leonidas C., additional, Lopez-Rosas, Aurora, additional, Han, Yu, additional, Balyasnikova, Irina V., additional, and Lesniak, Maciej S., additional

Published
2019
Full Text
View/download PDF

37. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia

Author

Beauchamp, Elspeth M., primary, Abedin, Sameem M., additional, Radecki, Sara G., additional, Fischietti, Mariafausta, additional, Arslan, Ahmet Dirim, additional, Blyth, Gavin T., additional, Yang, Angela, additional, Lantz, Connor, additional, Nelson, Alissa, additional, Goo, Young Ah, additional, Akpan, Imo, additional, Eklund, Elizabeth A., additional, Frankfurt, Olga, additional, Fish, Eleanor N., additional, Thomas, Paul M., additional, Altman, Jessica K., additional, and Platanias, Leonidas C., additional

Published
2019
Full Text
View/download PDF

38. IFN-γ–inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5

Author

Saleiro, Diana, primary, Blyth, Gavin T., additional, Kosciuczuk, Ewa M., additional, Ozark, Patrick A., additional, Majchrzak-Kita, Beata, additional, Arslan, Ahmet D., additional, Fischietti, Mariafausta, additional, Reddy, Neha K., additional, Horvath, Curt M., additional, Davis, Roger J., additional, Fish, Eleanor N., additional, and Platanias, Leonidas C., additional

Published
2018
Full Text
View/download PDF

41. GADD45β Loss Ablates Innate Immunosuppression in Cancer

Author

Verzella, Daniela, primary, Bennett, Jason, additional, Fischietti, Mariafausta, additional, Thotakura, Anil K., additional, Recordati, Camilla, additional, Pasqualini, Fabio, additional, Capece, Daria, additional, Vecchiotti, Davide, additional, D'Andrea, Daniel, additional, Di Francesco, Barbara, additional, De Maglie, Marcella, additional, Begalli, Federica, additional, Tornatore, Laura, additional, Papa, Salvatore, additional, Lawrence, Toby, additional, Forbes, Stuart J., additional, Sica, Antonio, additional, Alesse, Edoardo, additional, Zazzeroni, Francesca, additional, and Franzoso, Guido, additional

Published
2018
Full Text
View/download PDF

43. MicroRNAs in the DNA Damage/Repair Network and Cancer

Author

Tessitore, Alessandra, Cicciarelli, Germana, Del Vecchio, Filippo, Gaggiano, Agata, Verzella, Daniela, Fischietti, Mariafausta, Vecchiotti, Davide, Capece, Daria, Zazzeroni, Francesca, and Alesse, Edoardo

Subjects
Article Subject
Abstract

Cancer is a multistep process characterized by various and different genetic lesions which cause the transformation of normal cells into tumor cells. To preserve the genomic integrity, eukaryotic cells need a complex DNA damage/repair response network of signaling pathways, involving many proteins, able to induce cell cycle arrest, apoptosis, or DNA repair. Chemotherapy and/or radiation therapy are the most commonly used therapeutic approaches to manage cancer and act mainly through the induction of DNA damage. Impairment in the DNA repair proteins, which physiologically protect cells from persistent DNA injury, can affect the efficacy of cancer therapies. Recently, increasing evidence has suggested that microRNAs take actively part in the regulation of the DNA damage/repair network. MicroRNAs are endogenous short noncoding molecules able to regulate gene expression at the post-transcriptional level. Due to their activity, microRNAs play a role in many fundamental physiological and pathological processes. In this review we report and discuss the role of microRNAs in the DNA damage/repair and cancer.

Published
2014
Full Text
View/download PDF

45. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice

Author

Tessitore, Alessandra, primary, Cicciarelli, Germana, additional, Del Vecchio, Filippo, additional, Gaggiano, Agata, additional, Verzella, Daniela, additional, Fischietti, Mariafausta, additional, Mastroiaco, Valentina, additional, Vetuschi, Antonella, additional, Sferra, Roberta, additional, Barnabei, Remo, additional, Capece, Daria, additional, Zazzeroni, Francesca, additional, and Alesse, Edoardo, additional

Published
2016
Full Text
View/download PDF

47. Serum Biomarkers Identification by Mass Spectrometry in High-Mortality Tumors

Author

Tessitore, Alessandra, Gaggiano, Agata, Cicciarelli, Germana, Verzella, Daniela, Capece, Daria, Fischietti, Mariafausta, Zazzeroni, Francesca, and Alesse, Edoardo

Subjects
Article Subject
Abstract

Cancer affects millions of people worldwide. Tumor mortality is substantially due to diagnosis at stages that are too late for therapies to be effective. Advances in screening methods have improved the early diagnosis, prognosis, and survival for some cancers. Several validated biomarkers are currently used to diagnose and monitor the progression of cancer, but none of them shows adequate specificity, sensitivity, and predictive value for population screening. So, there is an urgent need to isolate novel sensitive, specific biomarkers to detect the disease early and improve prognosis, especially in high-mortality tumors. Proteomic techniques are powerful tools to help in diagnosis and monitoring of treatment and progression of the disease. During the last decade, mass spectrometry has assumed a key role in most of the proteomic analyses that are focused on identifying cancer biomarkers in human serum, making it possible to identify and characterize at the molecular level many proteins or peptides differentially expressed. In this paper we summarize the results of mass spectrometry serum profiling and biomarker identification in high mortality tumors, such as ovarian, liver, lung, and pancreatic cancer.

Published
2013
Full Text
View/download PDF

48. The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages

Author

Capece, Daria, Fischietti, Mariafausta, Verzella, Daniela, Gaggiano, Agata, Cicciarelli, Germana, Tessitore, Alessandra, Zazzeroni, Francesca, and Alesse, Edoardo

Subjects
stomatognathic system, Article Subject
Abstract

Hepatocellular carcinoma (HCC) is one of the most common and aggressive human cancers worldwide. HCC is an example of inflammation-related cancer and represents a paradigm of the relation occurring between tumor microenvironment and tumor development. Tumor-associated macrophages (TAMs) are a major component of leukocyte infiltrate of tumors and play a pivotal role in tumor progression of inflammation-related cancer, including HCC. Several studies indicate that, in the tumor microenvironment, TAMs acquire an M2-polarized phenotype and promote angiogenesis, metastasis, and suppression of adaptive immunity through the expression of cytokines, chemokines, growth factors, and matrix metalloproteases. Indeed, an established M2 macrophage population has been associated with poor prognosis in HCC. The molecular links that connect cancer cells and TAMs are not completely known, but recent studies have demonstrated that NF-κB, STAT-3, and HIF-1 signaling pathways play key roles in this crosstalk. In this paper, we discuss the current knowledge about the role of TAMs in HCC development, highlighting the role of TAM-derived cytokines, chemokines, and growth factors in the initiation and progression of liver cancer and outlining the signaling pathways involved in the interplay between cancer cells and TAMs.

Published
2013
Full Text
View/download PDF

49. Slfn2 Regulates Type I Interferon Responses by Modulating the NF-6B Pathway.

Author

Fischietti, Mariafausta, Arslan, Ahmet D., Sassano, Antonella, Saleiro, Diana, Majchrzak-Kit, Beata, Ebine, Kazumi, Munshi, Hidayatullah G., Fish, Eleanor N., and Platanias, Leonidas C.

Subjects
*INTERFERONS, *ANTIVIRAL agents, *GENETIC transcription, *GENETIC regulation, *GENE expression, *MARKETING
Abstract

Although members of the Slfn family have been implicated in the regulation of type I interferon (IFN) responses, the mechanisms by which they mediate their effects remain unknown. In the present study, we provide evidence that targeted disruption of the Slfn2 gene leads to increased transcription of IFN-stimulated genes (ISGs) and enhanced type I IFN-mediated antiviral responses. We demonstrate that Slfn2 interacts with protein phosphatase 6 regulatory subunit 1 (PPP6R1), leading to reduced type I IFN-induced activation of nuclear factor kappa B (NF-κB) signaling, resulting in reduced expression of ISGs. Altogether, these data suggest a novel mechanism by which Slfn2 controls ISG expression and provide evidence for a critical role for Slfn2 in the regulation of IFN-mediated biological responses. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

50. Targeting Costimulatory Molecules to Improve Antitumor Immunity

Author

Capece, Daria, Verzella, Daniela, Fischietti, Mariafausta, Zazzeroni, Francesca, and Alesse, Edoardo

Subjects
Article Subject
Abstract

The full activation of T cells necessitates the concomitant activation of two signals, the engagement of T-cell receptor by peptide/major histocompatibility complex II and an additional signal delivered by costimulatory molecules. The best characterized costimulatory molecules belong to B7/CD28 and TNF/TNFR families and play crucial roles in the modulation of immune response and improvement of antitumor immunity. Unfortunately, tumors often generate an immunosuppressive microenvironment, where T-cell response is attenuated by the lack of costimulatory molecules on the surface of cancer cells. Thus, targeting costimulatory pathways represent an attractive therapeutic strategy to enhance the antitumor immunity in several human cancers. Here, latest therapeutic approaches targeting costimulatory molecules will be described.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results